Bernstein Liebhard LLP announced a class action lawsuit against Zoetis Inc. for allegedly making false and misleading statements about its business and financial health between January 14, 2025, and May 6, 2026. The lawsuit claims these misrepresentations inflated Zoetis' stock price, causing investors to suffer losses when the truth emerged. Investors who purchased Zoetis securities during this period are encouraged to contact the law firm to discuss their rights and possibly join the lawsuit. The deadline to file as lead plaintiff is July 27, 2026.
Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Zoetis securities between January 14, 2025, and May 6, 2026. The lawsuit alleges that Zoetis made false or misleading statements about the market performance and ado...
A class action lawsuit has been filed against Zoetis Inc. and certain officers, alleging they made false statements about the growth and market share of key products in the Companion Animal segment. The complaint claims Zoetis failed to disclose weak...
Zoetis Inc. is the subject of a class action lawsuit alleging it misled investors about weakening sales of key animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint. The lawsuit claims Zoetis and its executives failed to d...
A class action lawsuit has been filed against Zoetis Inc. alleging the company misled investors about the strength of its Companion Animal segment. The lawsuit claims Zoetis portrayed this segment as a strong growth driver while hiding safety concern...
A class action lawsuit has been filed against Zoetis Inc. for allegedly misleading investors about the performance of its main animal health products, including Librela, Simparica Trio, Apoquel, and Cytopoint. The complaint claims Zoetis failed to di...
